Sarepta FDA Investigation

News

US FDA Investigates 3rd Death

FDA Probes Death of Boy in Brazil on Sarepta’s Elevidys

US regulators are investigating the death of an 8-year-old boy in Brazil who received Sarepta Therapeutics Inc.’s Elevidys.

· 35m · on MSN

FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy

· 41m

US FDA Investigates Third Death After Treatment With Sarepta's Gene Therapy Elevidys

PharmExec2d

Recapping the Sarepta Saga—And Implications for Industry

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Sarepta shares plunge 40% as future of its gene therapy appears at risk

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

The Business Journals1mon

FDA says it's investigating Sarepta’s Duchenne patient deaths

The Food and Drug Administration is conducting an investigation following the deaths of two patients treated with Sarepta's gene therapy for Duchenne muscular dystrophy. Thursday, July 31, 2025 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results